publication date: Jan. 25, 2017
Pancreatic Cancer Halozyme’s Phase II Study In Advanced Pancreas Cancer Meets Endpoints
Halozyme Therapeutics Inc. reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a phase II randomized, multi-center clinical trial of lead investigational drug PEGPH20 in combination with ABRAXANE(nab-paclitaxel) and gemcitabine in stage IV pancreas cancer patients.
Among the findings, the overall study population showed a statistically significant increase in progression-free survival in patients with high levels of hyaluronan treated with PEGPH20 plus ABRAXANE and gemcitabine when compared to HA-High patients receiving ABRAXANE and gemcitabine alone.
Stage 2 of the study, which completed enrollment in February 2016, showed a 91 percent improvement in median PFS for HA-High patients in the PEGPH20 arm, 8.6 months compared to 4.5 months in the control arm, and achieved its primary endpoint to evaluate and demonstrate a reduction in the rate of thromboembolic events in the PEGPH20 arm.
“These findings confirm our confidence in the development of PEGPH20 to treat cancer,” said Helen Torley, president and CEO. “We are pleased by the overall consistency of both the efficacy and safety data which are supportive of our ongoing Phase 3 clinical trial, HALO 301, currently underway at more than 160 sites worldwide.”
Sunil Hingorani, the trial’s principal investigator and a pancreas cancer expert at Fred … Continue reading CCL Jan 2017 – Halozyme’s Phase II Study In Advanced Pancreas Cancer Meets Endpoints
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.